SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GenVec - GNVC
GNVC 7.1930.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Gary Mohilner4/16/2010 5:16:23 PM
   of 106
 
Could halting enrollment in all TNFerade Trials have been a stroke of genius.

With the failure of the PACT Trial, I don't believe that halting enrollment in other trials cost investors more than a couple cents. Fast forward a couple weeks or a month, won't each trial that resumes recruitment provide a positive opportunity to say why.

Unless some trials truly aren't showing positive data, I believe that restarting them will be positive, and ideally each one will individually be treated with a PR announcing it's be restarted, with at least top line data announcing why.

I'm not suggesting that we'll go over $3 in the restart of recruiting in all the trials outside of PACT, but perhaps we'll regain over half the loss shortly. A partnership, or news not related to TNFerade that's positive may be all we need to see new 52 week highs again.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News